PSNL

SEC source: 0001209191-21-033479 · doc4.xml · derivative · entry 2

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2031-05-15

F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments with the first installment vesting on June 15, 2021.

SEC source: 0001209191-21-033479 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,372

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest in 8 equal semi-annual installments with the first installment vesting on November 15, 2021.

F2 · balance_after: Includes 538 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on April 30, 2021.

SEC source: 0001209191-21-033485 · doc4.xml · derivative · entry 2

BOWMAN A BLAINE · CIK 0001008891 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229

Underlying: Common Stock · 4,229 shares

Expires 2031-05-14

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033485 · doc4.xml · nonDerivative · entry 1

BOWMAN A BLAINE · CIK 0001008891 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,736

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033498 · doc4.xml · derivative · entry 2

MYERS WOODROW A JR · CIK 0001243399 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229

Underlying: Common Stock · 4,229 shares

Expires 2031-05-14

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033498 · doc4.xml · nonDerivative · entry 1

MYERS WOODROW A JR · CIK 0001243399 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,346

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033496 · doc4.xml · derivative · entry 2

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229

Underlying: Common Stock · 4,229 shares

Expires 2031-05-14

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033496 · doc4.xml · nonDerivative · entry 1

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,736

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033492 · doc4.xml · derivative · entry 3

LUDLUM KEN · CIK 0001255825 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229

Underlying: Common Stock · 4,229 shares

Expires 2031-05-14

F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033492 · doc4.xml · nonDerivative · entry 1

LUDLUM KEN · CIK 0001255825 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,736

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033489 · doc4.xml · derivative · entry 2

Colowick Alan · CIK 0001316163 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229

Underlying: Common Stock · 4,229 shares

Expires 2031-05-14

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033489 · doc4.xml · nonDerivative · entry 1

Colowick Alan · CIK 0001316163 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,736

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033495 · doc4.xml · derivative · entry 2

MacQuitty Jonathan · CIK 0001779844 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,229

Underlying: Common Stock · 4,229 shares

Expires 2031-05-14

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control.

SEC source: 0001209191-21-033495 · doc4.xml · nonDerivative · entry 1

MacQuitty Jonathan · CIK 0001779844 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,736

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control.

SEC source: 0001209191-21-025313 · doc4.xml · derivative · entry 5

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,945

Underlying: Common Stock · 12,517 shares

Expires 2022-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The Shares subject to the option are fully vested and exercisable.

SEC source: 0001209191-21-025313 · doc4.xml · nonDerivative · entry 4

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,834

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-21-025313 · doc4.xml · nonDerivative · entry 3

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-025313 · doc4.xml · nonDerivative · entry 2

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,834

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The weighted average sale price for the transaction reported was $25.96, and the range of prices were between $25.86 and $26.20. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-025313 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,094

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The weighted average sale price for the transaction reported was $25.61, and the range of prices were between $24.84 and $25.82. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-022149 · doc4.xml · nonDerivative · entry 1

Tachibana Aaron · CIK 0001401786 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,823

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-21-022150 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,317

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-21-018685 · doc4.xml · derivative · entry 2

MYERS WOODROW A JR · CIK 0001243399 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,719

Underlying: Common Stock · 3,719 shares

Expires 2031-03-06

F2 · derivative.exercise_date: The shares subject to the option vest in 3 annual installments starting on March 6, 2022.

SEC source: 0001209191-21-018685 · doc4.xml · nonDerivative · entry 1

MYERS WOODROW A JR · CIK 0001243399 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,610

F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest in 3 annual installments with the first installment vesting on March 6, 2022.

SEC source: 0001209191-21-018010 · doc4.xml · nonDerivative · entry 1

Tachibana Aaron · CIK 0001401786 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,269

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-21-018009 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,447

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-22-014995 · doc4.xml · derivative · entry 2

Bloom Olivia Kyusuk · CIK 0001501545 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,691

Underlying: Common Stock · 15,691 shares

Expires 2032-03-01

F2 · derivative.exercise_date: The shares subject to the option vest in 3 annual installments with the first installment vesting on March 1, 2023.

SEC source: 0001209191-21-007439 · doc4.xml · derivative · entry 6

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,462

Underlying: Common Stock · 13,422 shares

Expires 2022-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The Shares subject to the option are fully vested and exercisable.

SEC source: 0001209191-21-007439 · doc4.xml · nonDerivative · entry 5

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,792

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan by the reporting person.

F5 · price: The weighted average sale price for the transaction reported was $38.80, and the range of prices were between 38.58 and 39.28. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007439 · doc4.xml · nonDerivative · entry 4

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,814

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan by the reporting person.

F4 · price: The weighted average sale price for the transaction reported was $38.12, and the range of prices were between 37.56 and 38.54. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007439 · doc4.xml · nonDerivative · entry 3

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-007439 · doc4.xml · nonDerivative · entry 2

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,792

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan by the reporting person.

F3 · price: The weighted average sale price for the transaction reported was $38.83, and the range of prices were between 38.57 and 39.28. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-21-007439 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,851

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan by the reporting person.

F2 · price: The weighted average sale price for the transaction reported was $38.19, and the range of prices were between 37.56 and 38.54. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-20-064703 · doc4.xml · nonDerivative · entry 1

Tachibana Aaron · CIK 0001401786 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,291

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-20-064704 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,370

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-20-061666 · doc4.xml · nonDerivative · entry 1

Tachibana Aaron · CIK 0001401786 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,682

F1 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-20-061669 · doc4.xml · nonDerivative · entry 4

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,457

F4 · kind: Shares sold to cover tax obligation from settlement of vested restricted stock units.

SEC source: 0001209191-20-061666 · doc4.xml · derivative · entry 2

Tachibana Aaron · CIK 0001401786 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-12-01

F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments starting on April 16, 2023.

SEC source: 0001209191-20-061669 · doc4.xml · derivative · entry 6

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-12-01

F6 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments starting on April 16, 2023.

SEC source: 0001209191-20-061669 · doc4.xml · derivative · entry 5

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,884

Underlying: Common Stock · 40,000 shares

Expires 2022-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

SEC source: 0001209191-20-061669 · doc4.xml · nonDerivative · entry 3

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,750

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The weighted average sale price for the transaction reported was $28.14, and the range of prices were between $28.025 and $28.43. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-20-061669 · doc4.xml · nonDerivative · entry 2

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,362

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The weighted average sale price for the transaction reported was $27.75, and the range of prices were between $27.02 and $28.01. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-20-061669 · doc4.xml · nonDerivative · entry 1

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000905718-20-001059 · personalis_fm4oct202020.xml · nonDerivative · entry 1

Abingworth LLP · CIK 0001397144 · Former 10% Owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,753,340

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-001057 · personalis_fm4oct162020.xml · nonDerivative · entry 2

Abingworth LLP · CIK 0001397144 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,883,826

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $28.80 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-001057 · personalis_fm4oct162020.xml · nonDerivative · entry 1

Abingworth LLP · CIK 0001397144 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,080,249

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $27.27 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-001051 · personalis_fm4oct142020.xml · nonDerivative · entry 2

Abingworth LLP · CIK 0001397144 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,174,467

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $26.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-001051 · personalis_fm4oct142020.xml · nonDerivative · entry 1

Abingworth LLP · CIK 0001397144 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,178,167

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.31 to $29.07 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-001041 · personalis_fm4oct122020a.xml · nonDerivative · entry 2

Abingworth LLP · CIK 0001397144 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,260,092

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.42 to $29.19 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-001041 · personalis_fm4oct122020a.xml · nonDerivative · entry 1

Abingworth LLP · CIK 0001397144 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,346,911

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $30.72 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · ownership.nature: The shares are held by Abingworth Bioventures V LP ("Abingworth V"). Abingworth Bioventures V GP LP ("Abingworth GP") serves as the general partner of Abingworth V. Abingworth General Partner V LLP, serves as the general partner of Abingworth GP. Abingworth V (acting by its general partner, Abingworth GP, acting by its general partner, Abingworth General Partner V LLP) has delegated to Abingworth LLP ("ALLP"), all investment and dispositive power over the securities held by Abingworth V. ALLP holds the reported securities indirectly through Abingworth V. ALLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that the reporting person, Abingworth V or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-20-053885 · doc4.xml · derivative · entry 4

Chen Richard · CIK 0001779787 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,884

Underlying: Common Stock · 37,452 shares

Expires 2022-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.